Proyecto CDTI: Investigación de una nueva vacuna para una enfermedad respiratoria humana

Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. y Nostrum Biodiscovery constituyen el consorcio de empresas que participan en el proyecto “Investigación de una nueva vacuna para una enfermedad respiratoria humana”, subvencionado por el CDTI (Centro para el Desarrollo Tecnológico Industrial), apoyado por el Ministerio de Ciencia e Innovación y financiado por la Unión Europea – NextGenerationEU. El objetivo general del proyecto consiste en el diseño de una vacuna que sea segura, inmunogénica y eficaz frente al virus respiratorio sincitial.

Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. i Nostrum Biodiscovery constiutuixen el consorci d’empreses que participen en el projecte “Investigació d’una nova vacuna per una malaltia respiratòria humana”, subvencionat pel CDTI (Centre pel Desenvolupament Tecnològic Industrial), recolzat pel Ministeri de Ciència i Innovació i finançat per la Unió Europea – NextGenerationEU. L’objectiu general del projecte consisteix en el disseny d’una vacuna segura, immunogènica i eficaç contra el virus respiratori sincitial.

Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. and Nostrum Biodiscovery constitute the consortium of enterprises participating in the project “Research of a new vaccine for a human respiratory disease”,  granted by the CDTI (Center for Industrial Technological Development), and supported by the Ministry of Science and Innovation and financed by the European Union – NextGenerationEU. The main objective of this project is to design a safe immunogenic and effective vaccine against the respiratory syncytial virus.

The Latest from Curapath
Curapath Strengthens PEG-Free Delivery Platform Through Exclusive Agreement with Calusa Bio

Curapath has entered into an exclusive license agreement with Calusa Bio, LLC, further strengthening its PEG alternative toolbox with a novel and differentiated technology. This strategic...

Curapath and Cayman Chemical Partner to Expand Access to PEG-Free Shielding Lipids for Advanced LNP Formulations

VALENCIA, SPAIN, SEPTEMBER 2, 2025 At Curapath, our mission has always been to push the boundaries of non-viral drug delivery. Today, we are proud to announce...

7 Questions with Philippe Clavel: What Matters Most to a CEO Leading Through Transformation

The CDMO journey is never just operational, it’s human. In this 7-question Q&A, Philippe Clavel, CEO of Curapath, shares his reflections on the first half of...